Innospera Pharma
Innospera Pharma is a privately held biotechnology company based in Montreal, focused on developing small-molecule modulators targeting G-protein coupled receptors (GPCRs), particularly GPR84 and GPR40, for the treatment of chronic, fibrotic, inflammatory, and metabolic diseases. Its pipeline includes next-generation lipid-mimetic compounds designed to address unmet medical needs, with lead candidates intended for conditions such as idiopathic pulmonary fibrosis and various cardiometabolic disorders. The company leverages extensive scientific expertise and preclinical data and is supported by investors such as Investissement Québec, Seido Capital, and Anges Québec.
What We Do
A pipeline of small-molecule GPCR modulators, with a lead compound in late preclinical development for idiopathic pulmonary fibrosis as well as additional candidates for cardiometabolic and chronic conditions.
A pipeline of small-molecule GPCR modulators, with a lead compound in late preclinical development for idiopathic pulmonary fibrosis as well as additional candidates for cardiometabolic and chronic conditions.
Application Area
Regenerative Medicine
Drugs
Key People
News & Updates
Recognized with Investment of the Year Award at Anges Québec 2025 for innovation and potential in biotechnology.
Received 'Investment of the Year' at the Anges Québec 2025 Annual Meeting, recognizing contributions to biotech innovation in Quebec.
Appointment of Dr. Glenn Crater as Chief Medical Officer to support clinical advancement of lead candidate.
Chief Scientific Officer to present new preclinical data for a novel GPCR modulator at ATS 2025 Annual Meeting.
François Ravenelle, PhD appointed as President and CEO to lead company through next growth phase.
Recognized with Investment of the Year Award at Anges Québec 2025 for innovation and potential in biotechnology.
Received 'Investment of the Year' at the Anges Québec 2025 Annual Meeting, recognizing contributions to biotech innovation in Quebec.
Appointment of Dr. Glenn Crater as Chief Medical Officer to support clinical advancement of lead candidate.
Chief Scientific Officer to present new preclinical data for a novel GPCR modulator at ATS 2025 Annual Meeting.
François Ravenelle, PhD appointed as President and CEO to lead company through next growth phase.